A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
Participant data from three independent studies were evaluated: the Parkinson's Progression Markers Initiative (PPMI), the ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
BioArctic begins patient dosing in EXIST phase 2a study in Parkinson’s disease: Stockholm Saturday, December 7, 2024, 18:00 Hrs [IST] BioArctic AB (publ), a Swedish research-bas ...
SPR301 is a potential best-in-class gene therapy candidate that delivers a more stable, rationally engineered version of GCase, the enzyme ...
Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including ...